

**MEDIA RELEASE – 24 AUGUST 2022**
**FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2022**
**1. Summary**

<b>A\$M</b>	<b>FY2022</b>	<b>Increase on FY 2021</b>
Revenue	<b>9,340</b>	7%
EBITDA	<b>2,830</b>	11%
Net Profit	<b>1,461</b>	11%
Cash generated from operations	<b>2,226</b>	9%
Earnings per share (AUD cents)	<b>302.5</b>	11%

- Record revenue and earnings driven by COVID testing, base business growth and acquisitions.
- A\$628 million invested in synergistic acquisitions and joint ventures in the year, with further opportunities being pursued.
- Base business revenue (ex-COVID testing) up 2.1% versus FY2021 and 5.5% versus FY2019 (constant currency, organic growth).
- COVID revenue up 13% (constant currency) versus FY2021.
- Gearing at record low level, ~A\$1.6 billion of available liquidity, on-market share buy-back of up to A\$500 million well progressed as part of active capital management.
- Total dividends for the year of \$1.00, up 10% on the prior year. Final (H2) dividend of \$0.60, up 9%. FY2022 dividends franked to 100%. Progressive dividend policy maintained.

**2. Commentary**

Sonic Healthcare today reported a record net profit for the year to 30 June 2022 of A\$1.5 billion, on revenues of A\$9.3 billion.

Sonic's CEO, Dr Colin Goldschmidt, said: "Sonic Healthcare and our people have continued to play a major role in combating the COVID-19 pandemic during the 2022 financial year. Since the start of the pandemic we have performed over 55 million COVID-19 PCR tests across our seven countries of operation, in addition to providing COVID-related antibody testing, genetic sequencing and vaccination services. Concurrently, we have also provided non-COVID essential medical diagnostic services for more than 100 million patients a year. Throughout this challenging period our staff have been unified by our culture of Medical Leadership, which focuses on providing the best possible care for our patients and service for their physicians. Our culture serves to inspire our staff to exceptional service and provides us with competitive advantage in our global markets. I would like to express my great appreciation and admiration for our staff for the way they embrace and enhance our culture and values, even in the most difficult of times.

"Sonic's revenue grew organically by 5% for the year, with base business organic growth of 2.1% augmented by significant growth in COVID-related revenues. The contributions of synergistic acquisitions took total growth for the year to 7%. Twelve months ago, we would never have expected our COVID-related revenues to grow by 13% in 2022. It remains difficult to predict future revenues from COVID-19 testing, however we do expect ongoing demand, coupled with seasonally weighted increased testing for other respiratory viruses.

“Barring a significant worsening of the pandemic, we also expect our base business growth to accelerate, driven by the normal strong industry growth drivers, market share gains and the clearing of backlogged testing postponed during the pandemic.

“The results for the 2022 year clearly demonstrated the operating leverage in Sonic’s business, with EBITDA and Net Profit growth of 11% on 7% revenue growth. Sonic’s strong cashflow generation over the last 2 years has enabled us to achieve a record low level of gearing of the company, whilst maintaining our progressive dividend policy, investing in growth, and conducting an on-market share buyback. We have repaid all bank debt and have no current exposure to interest rate rises as our remaining debt is fixed rate and long term.

“Our management teams around the world continue to focus on identifying and assessing potential growth opportunities, including synergistic acquisitions and outsourcing contracts. As is usually the case, we are currently considering several potential opportunities. During the 2022 financial year Sonic invested A\$628 million in acquisitions and joint ventures to enhance growth and create synergy opportunities, including the acquisitions of Canberra Imaging Group and ProPath, which have substantially strengthened our Radiology division and our USA anatomical pathology operations, respectively.

“Sonic also acquired a 20% strategic equity stake in Harrison.ai and established our joint venture, Franklin.ai, to develop best-in-class AI diagnostic tools for pathology. With the support and expertise of Sonic and Harrison.ai, Franklin.ai has been ramping up at pace and is targeting its first product release within 2 years.

“Sonic’s sustainability initiatives continue to gain momentum following formalisation during the year of sustainability governance and management structures at board, executive and operational levels. The Sonic Sustainability Steering Committee has identified the company’s material sustainability topics and our net zero strategy. These will be detailed, along with other updates, in Sonic’s 2022 Sustainability Report to be released in November 2022.”

**Dr Colin Goldschmidt**

Chief Executive Officer / Managing Director

Sonic Healthcare Limited

Ph.: (02) 9855 5333

This announcement has been authorised by the Board of Directors of Sonic Healthcare Limited – please refer to the contact details above.

*For further information regarding the result, please refer to Dr Goldschmidt’s PowerPoint Presentation and to Sonic’s FY2022 Appendix 4E Preliminary Final Report, both of which will be posted on the Sonic Healthcare website by 9.00am, 24 August 2022 ([www.sonichealthcare.com](http://www.sonichealthcare.com)).*

**Forward-looking statements**

*This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts, unexpected growth in costs and expenses and the progress of the COVID-19 pandemic. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements.*